KemPharm (KMPH) Stock Rating Upgraded by Zacks Investment Research
Zacks Investment Research upgraded shares of KemPharm (NASDAQ:KMPH) from a hold rating to a buy rating in a report issued on Tuesday morning. They currently have $5.00 price objective on the specialty pharmaceutical company’s stock.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
KMPH has been the topic of several other research reports. Cowen cut shares of KemPharm from an outperform rating to a hold rating in a research note on Monday, July 9th. ValuEngine upgraded shares of KemPharm from a hold rating to a buy rating in a research note on Thursday, August 2nd. Oppenheimer began coverage on shares of KemPharm in a research note on Friday, September 21st. They issued an outperform rating on the stock. Canaccord Genuity reiterated a buy rating and issued a $11.00 price target on shares of KemPharm in a research note on Tuesday, August 14th. Finally, CIBC reiterated an outperform rating on shares of KemPharm in a research note on Friday, September 21st. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $10.50.
KemPharm (NASDAQ:KMPH) last announced its quarterly earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.31. equities analysts expect that KemPharm will post -2.95 earnings per share for the current fiscal year.
In other KemPharm news, major shareholder Delaware Street Capital Master bought 304,283 shares of KemPharm stock in a transaction dated Monday, July 30th. The shares were purchased at an average cost of $4.00 per share, for a total transaction of $1,217,132.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 25.90% of the company’s stock.
Several institutional investors have recently bought and sold shares of KMPH. Millennium Management LLC bought a new stake in shares of KemPharm in the 1st quarter worth about $122,000. Spark Investment Management LLC bought a new stake in shares of KemPharm in the 2nd quarter worth about $176,000. Royal Bank of Canada increased its holdings in shares of KemPharm by 1,847.1% in the 1st quarter. Royal Bank of Canada now owns 24,125 shares of the specialty pharmaceutical company’s stock worth $191,000 after buying an additional 22,886 shares during the last quarter. Change Path LLC bought a new stake in shares of KemPharm in the 1st quarter worth about $479,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of KemPharm by 15,976.2% in the 1st quarter. JPMorgan Chase & Co. now owns 100,637 shares of the specialty pharmaceutical company’s stock worth $795,000 after buying an additional 100,011 shares during the last quarter. Hedge funds and other institutional investors own 39.15% of the company’s stock.
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.
Featured Story: How do investors use RSI to grade stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.